National Haemoglobinopathy Panel

Providing expert and evidence-based advice on the management of adults and children with Sickle Cell Disease, Thalassaemia and Rare Inherited Anaemias, as and when requested by the clinicians caring for these patients.

Over-Project.png

The NHP Multidisciplinary Team (MDT) with membership drawn from Haemoglobinopathy Coordinating Centres (HCC) aims to:

  1. Drive the delivery of a nationally consistent approach to care envisaged by the Clinical Reference Group and approved by commissioners

  2. Coordinate the actions taken at Specialist Haemoglobinopathies Teams (SHT) and Haemoglobinopathies Coordinating Centres (HCC) levels to deliver access to specialist oversight and to reduce unwarranted variation

  3. Provide SHT and HCC access to national expert clinical opinion with regard to the treatment of complex patients

  4. Support the introduction of commissioned innovative therapies by acting as a national panel to consider individual patients most able to benefit and to enable patients to have access to these therapies, irrespective of where they live.

Driving Innovation and Quality

The NHP will monitor relevant data at a national level and promote access to novel therapies and clinical trials for all patients, regardless of geography.